You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

Certaines de ces informations ou toutes, dans certains cas, n’apparaissent qu’en Anglais. Vous pouvez demander la version française

Funded Evidence-Informed Regimens

Drug and regimen monographs and information sheets for patients provide information on dosing and administering cancer treatment protocols. They are for general reference and are not meant to replace prescribing information or physician recommendations.

If you have questions about ST-QBP funding on our website, please visit our Frequently Asked Questions page.

Find enhanced Regimen Patient Information Sheets, created in collaboration with patient and family advisors.

Regimens

17 Items
Cancer Type: Lung, Non-Small Cell     
Intent: Palliative
Funding:
New Drug Funding Program
    Pemetrexed - Combination with Platinum for Non-Small Cell Lung Cancer
Updated
Nov 2019
Cancer Type: Skin, Melanoma     
Intent: Palliative
Funding:
Exceptional Access Program
    cobimetinib - For combination therapy (with vemurafenib) for the treatment of patients with previously untreated BRAF V600 mutation-positive unresectable stage III or IV melanoma
Exceptional Access Program
    vemURAFenib- For combination therapy (with cobimetinib) for the treatment of patients with previously untreated BRAF V600 mutation-positive unresectable stage Ill or stage IV melanoma
May 2019
Cancer Type: Lung, Non-Small Cell     
Intent: Palliative
Aug 2019
Cancer Type: Lung, Non-Small Cell     
Intent: Palliative
Funding:
New Drug Funding Program
    Pemetrexed - Combination with Platinum for Non-Small Cell Lung Cancer
Updated
Nov 2019
Cancer Type: Genitourinary, Prostate     
Intent: Palliative
Funding:
ODB - General Benefit
  • flutamide
Oct 2016
Cancer Type: Breast     
Intent: Palliative
Funding:
ODB - General Benefit
  • megestrol - oral tablets
May 2016
Cancer Type: Gynecologic, Endometrial     
Intent: Palliative
Funding:
ODB - General Benefit
  • megestrol - oral tablets
Oct 2017
Cancer Type: Gynecologic, Endometrial     
Intent: Adjuvant, Curative
Funding:
ODB - General Benefit
    megestrol - oral tablets
May 2019
Cancer Type: Gynecologic, Endometrial     
Intent: Palliative
Funding:
ODB - General Benefit
    megestrol - oral tablets
ODB - General Benefit
    tamoxifen
May 2019
Cancer Type: Skin, Melanoma     
Intent: Palliative
Funding:
New Drug Funding Program
    Pembrolizumab - Advanced Melanoma (Unresectable or Metastatic Melanoma) and No Prior Ipilimumab
New Drug Funding Program
    Pembrolizumab - Advanced Melanoma (Unresectable or Metastatic Melanoma) and Prior Ipilimumab
Sep 2019
Cancer Type: Lung, Non-Small Cell     
Intent: Palliative
Funding:
New Drug Funding Program
    Pembrolizumab - Advanced or Metastatic Non-Small Cell Lung Cancer (Second or Subsequent Line)
New Drug Funding Program
    Pembrolizumab - Previously Untreated Locally Advanced or Metastatic Non-Small Cell Lung Cancer
Sep 2019
Cancer Type: Skin, Melanoma     
Intent: Adjuvant
Drugs Used:
pembrolizumab (Unfunded)
Updated
Nov 2019